Co-Diagnostics Gestion
Gestion contrôle des critères 4/4
Le PDG Co-Diagnostics est Dwight Egan, nommé en Apr2013, a un mandat de 13.17 ans. La rémunération annuelle totale est $ 528.75K, composée du salaire de 75.7% et des bonus 24.3%, y compris les actions et options de la société. détient directement 0.76% des actions de la société, d'une valeur de $ 119.66K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 2.2 ans et 6.9 ans.
Informations clés
Dwight Egan
Directeur général
US$528.8k
Rémunération totale
| Pourcentage du salaire du PDG | 75.65% |
| Durée du mandat du directeur général | 13.2yrs |
| Propriété du PDG | 0.8% |
| Durée moyenne d'occupation des postes de direction | 2.2yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 6.9yrs |
Mises à jour récentes de la gestion
Recent updates
Regulatory Approvals And Launches Will Expand Decentralized Healthcare Access
Narrative Update on Co-Diagnostics Analysts have marginally increased their price target for Co-Diagnostics from $3.00 to $3.00, citing minimal changes in valuation inputs and updated financial forecasts as the rationale for this slight adjustment. What's in the News Announced development of a proprietary sample preparation instrument to streamline its point-of-care Co-Dx PCR Mycobacterium Tuberculosis Test.Regulatory Approvals And Launches Will Expand Decentralized Healthcare Access
Analysts have significantly lowered their price target for Co-Diagnostics from $10.00 to $3.00, citing revised fair value estimates and a reduced expectation for future earnings multiples. What's in the News Co-Diagnostics completed a $3.85 million Follow-on Equity Offering, issuing 9,619,000 shares of common stock at $0.40 per share in a registered direct offering.
Co-Dx PCR Platform And FDA 510(K) Clearance Will Expand Market Reach
Advancements in PCR platform and manufacturing enhance commercialization, potentially increasing revenues and profit margins through scale efficiencies.Is Co-Diagnostics (NASDAQ:CODX) In A Good Position To Deliver On Growth Plans?
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Here's Why We're Watching Co-Diagnostics' (NASDAQ:CODX) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...One Co-Diagnostics, Inc. (NASDAQ:CODX) Analyst Just Slashed Their Estimates By A Consequential 14%
One thing we could say about the covering analyst on Co-Diagnostics, Inc. ( NASDAQ:CODX ) - they aren't optimistic...A Look At The Intrinsic Value Of Co-Diagnostics, Inc. (NASDAQ:CODX)
Key Insights Co-Diagnostics' estimated fair value is US$1.40 based on 2 Stage Free Cash Flow to Equity Current share...Co-Diagnostics: Hold Thesis Remains Well Intact
Summary We reiterate the hold thesis on Co-Diagnostics following Q2 FY22 earnings. Covid-19 turnover continues to diminish for CODX whilst surging for rival test providers. Inventory levels for the company spiked year over year as the Omicron-led demand in testing faded. We've valued CODX at $3.24 suggesting shares are adequately priced by the market consensus. From the Portfolio Manager's Desk Having witnessed the rapid cooling of Omicron-led demand in Covid-19 diagnostics, the Sars-CoV-2 assay market is looking increasingly unattractive. Here revisit Co-Diagnostics, Inc. (CODX) a name that we are extremely familiar with having tracked the company across the entire span of the pandemic. We were buyers of the stock in January FY21 as a speculative position built around our core holdings in med-tech. We've since exited the position with a small loss, and believe impeding macro-headwinds remain for the company. With Covid-assay demand still diminishing, supplier inventory levels are likely at historically low levels, and the question is if they will seek to restore/repurchase inventory levels back to FY21 highs. The bulk of CODX's turnover is derived from Covid-19, so this is key to the investment debate for CODX looking ahead. Investment Thesis Summary Here we reiterate a hold rating on CODX with a $3.24 price target. With Covid-19 test revenue diminishing substantially in Q2 FY22 [whilst rival test makers revenue surged YoY] there is low predictability of the company's future cash flows by estimation. Valuations are supportive of a neutral view and forward looking earnings are marred by the fact Covid-19 test volumes will likely dwindle as time goes on. Although it has other innovations in the pipeline, the timing and timeline for these are fluid for now and there's no concrete launch dates. We need further clarity on how CODX intends to distribute its top-line ex-Covid. Rate hold price target $3.24. Co-Diagnostics' Q2 earnings illustrate headwinds CODX came in with a fairly weak set of numbers when compared to Q2 FY21. It clipped revenue of just $5 million ("mm"), an 81.6% YoY decrease from $27.4mm the year prior. The substantial tightening at the top line came as demand for CODX's Logix Smart Covid-19 test, that was developed in response to the pandemic [more on this later]. CODX also recognized a 54% YoY decline in sales to third parties of ~$75,000. Quarterly gross profit margin narrowed by 9 percentage points to 81.8% following the tighter revenue and unit volumes whilst fixed production costs made up a larger portion of revenues. Moving down the P&L, OPEX also narrowed by ~36% YoY to $8.3mm secondary to lower variable expenditures tied to sales volume. Quarterly operating loss came in at $4.17mm down from a profit of ~$11.8mm the year prior, again from the lower revenues and a $353,000 YoY gain in depreciation and amortization expense. Meanwhile R&D investment for the quarter came in 16.7% lower to $3.9mm from a relatively high base in Q2 FY21, and the company also bought back $2.6mm of its own stock. It brought this down to a quarterly net loss of ~$2.7mm or -$0.08/share, down from a $9.7mm/ $0.34 per share after-tax profit last year. CODX did still see profitability from CFFO during the quarter. In fact, for the 6-months to Q2 FY22, it printed $9.4mm [$0.28/share] in cash from operations. However, also noted is that it added $2.9mm stock based compensation expense to this, whereas accounts receivable value jumped $8.56mm during this time. Free cash flow ("FCF") has narrowed on a sequential basis for the company and came in at $1.15mm for the quarter and $25.2mm for the TTM. However, one point to note is that its TTM return on invested capital ("ROIC") has remained in the double digits at 24.2% last quarter and comfortably covers CODX's WACC hurdle of ~6.2% by ~4 turns. As seen in Exhibit 1, ROIC has remained consistently high whilst FCF is reinvested heavily back into the business. Exhibit 1. Quarterly FCF continues to decline whilst TTM ROIC remains buoyant, albeit tightening as well. This adds a bullish tilt to the risk/reward calculus and provides a solid bedrock for the company to continue seeing return on its investments looking ahead. Data: HB Insights, CODX SEC Filings Outlook weakened on lower test demand As have previously outlined, Covid-19 provided CODX with stellar revenue and earnings leverage that was reflected in its numbers at the time. Previously, we advocated that CODX's test volumes should remain high as there was currently no test to distinguish between influenza and Covid-19, a tailwind for assay kit producers. Management remain equally as optimistic, per language from CEO Dwight Egan on the Q2 earnings call: This dramatic shift [decrease] in testing behavior was widely felt across the diagnostics industry. Experts believe other waves of COVID variants are all, but inevitable. However, the timing and severity are impossible to predict with every new variant, including the possibility of immune escape as variants and sub-variants by for dominance. In the U.S. alone, we are still seeing around a 100,000 new COVID cases reported per day, over 6,000 COVID-related hospital admissions and nearly 400 deaths, all evidence to date points to a resilient mutable virus with no indication it will go away and that we will be living with it for years to come." Clearly, however, the Omicron-led demand for assay volumes has subsided and this is reflected in inventory values of both manufacturers and suppliers of the tests. We see evidence of this in CODX's numbers as its inventory value increased ~135% YoY in the second quarter to $4.7mm.Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$49m |
| Dec 31 2025 | US$529k | US$400k | -US$47m |
| Sep 30 2025 | n/a | n/a | -US$32m |
| Jun 30 2025 | n/a | n/a | -US$36m |
| Mar 31 2025 | n/a | n/a | -US$36m |
| Dec 31 2024 | US$717k | US$392k | -US$38m |
| Sep 30 2024 | n/a | n/a | -US$41m |
| Jun 30 2024 | n/a | n/a | -US$38m |
| Mar 31 2024 | n/a | n/a | -US$39m |
| Dec 31 2023 | US$1m | US$375k | -US$35m |
| Sep 30 2023 | n/a | n/a | -US$43m |
| Jun 30 2023 | n/a | n/a | -US$38m |
| Mar 31 2023 | n/a | n/a | -US$32m |
| Dec 31 2022 | US$2m | US$366k | -US$14m |
| Sep 30 2022 | n/a | n/a | US$15m |
| Jun 30 2022 | n/a | n/a | US$28m |
| Mar 31 2022 | n/a | n/a | US$40m |
| Dec 31 2021 | US$2m | US$350k | US$37m |
| Sep 30 2021 | n/a | n/a | US$42m |
| Jun 30 2021 | n/a | n/a | US$46m |
| Mar 31 2021 | n/a | n/a | US$51m |
| Dec 31 2020 | US$1m | US$309k | US$42m |
| Sep 30 2020 | n/a | n/a | US$28m |
| Jun 30 2020 | n/a | n/a | US$10m |
| Mar 31 2020 | n/a | n/a | -US$6m |
| Dec 31 2019 | US$460k | US$275k | -US$6m |
Rémunération vs marché: La rémunération totale de Dwight ($USD 528.75K ) est dans la moyenne des entreprises de taille similaire sur le marché US ($USD 642.98K ).
Rémunération et revenus: La rémunération de Dwight a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.
PDG
Dwight Egan (73 yo)
Mr. Dwight H. Egan serves as the Chairman and is its President at Co-Diagnostics, Inc. and has been its Director since April 2013 and serves as its Chief Executive Officer since April 2013. Mr. Egan has be...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Chairman | 13.2yrs | US$528.75k | 0.76% $ 119.7k | |
| President | 2.3yrs | US$360.00k | 0.63% $ 99.1k | |
| CFO & Company Secretary | 5.3yrs | US$421.25k | 0.61% $ 96.0k | |
| Chief Operating Officer | 2.2yrs | pas de données | pas de données | |
| Vice President of Finance & Accounting | no data | pas de données | pas de données | |
| Chief Technology Officer | 2.2yrs | pas de données | pas de données | |
| Head of Investor Relations | no data | pas de données | pas de données | |
| Senior Vice President of Overseas Operations & Strategic Alliances | no data | pas de données | pas de données | |
| Chief Commercialization Officer | 2.2yrs | pas de données | pas de données |
Gestion expérimentée: L'équipe de direction de CODX est considérée comme expérimentée (ancienneté moyenne 2.2 ans).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Chairman | 13.2yrs | US$528.75k | 0.76% $ 119.7k | |
| Independent Director | 9.1yrs | US$137.75k | 0.29% $ 46.1k | |
| Chairman of Scientific Advisory Board | 4.3yrs | pas de données | pas de données | |
| Independent Director | 6.8yrs | US$137.75k | 0.29% $ 45.8k | |
| Member of Scientific Advisory Board | 4.3yrs | pas de données | pas de données | |
| Independent Director | 7yrs | US$137.75k | 0.30% $ 47.6k | |
| Independent Director | 7yrs | US$140.75k | 0.29% $ 45.8k | |
| Member of Scientific Advisory Board | 4.3yrs | pas de données | pas de données |
Conseil d'administration expérimenté: Les membres du conseil d'administration de CODX sont considérés comme expérimentés (ancienneté moyenne 6.9 ans).
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/06/14 19:24 |
| Cours de l'action en fin de journée | 2026/06/12 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Co-Diagnostics, Inc. est couverte par 2 analystes. 1 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Jason McCarthy | Maxim Group |
| James Sidoti | Sidoti & Company, LLC |